Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02676544 · ClinicalTrials.gov registry record · Phase 1
Prostate Embolization for Massive Benign Prostatic Hypertrophy (BPH)
A Phase 1 study, sponsored by Rhode Island Hospital.
- Terminated
- Registry status
- Phase 1
- Development phase
- 9
- Enrollment target
NCT02676544: Clinical Trial Phase 1 study, sponsored by Rhode Island Hospital.
NCT02676544 is a Phase 1 study that was terminated before completion, run by Rhode Island Hospital. The registered enrollment target is 9 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (85% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02676544, a Phase 1 study, was terminated before completion, sponsored by Rhode Island Hospital.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 9 participants
- Enrollment target
Study Summary
This is a prospective, open label single center feasibility study to demonstrate basic safety and effectiveness of prostate artery embolization for the treatment of symptomatic benign prostatic Hyperplasia (BPH) in a small series of patients with large (≥90 grams) glands.
Primary Outcome
Questionnaire
Interventions
- DEVICE Embosphere microspheres
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2015-12 |
| Est. Completion | 2021-06-30 |
| Phase | Phase 1 |
Why NCT02676544 stopped before completion
NCT02676544 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 9 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (85% lower).
The record links to 0 conditions, and to 1 intervention - of which Embosphere microspheres is the first listed.
NCT02676544 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02676544 about?
NCT02676544 is a clinical study titled "Prostate Embolization for Massive Benign Prostatic Hypertrophy (BPH)". This is a prospective, open label single center feasibility study to demonstrate basic safety and effectiveness of prostate artery embolization for the treatment of symptomatic benign prostatic Hyperplasia (BPH) in a small series of patients with large (≥90 grams) glands.
What is the current status of trial NCT02676544?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 9 participants. The study started on 2015-12. Estimated completion is 2021-06-30.
What interventions are being tested in trial NCT02676544?
The interventions under investigation include: Embosphere microspheres (DEVICE).
Who is sponsoring clinical trial NCT02676544?
This trial is sponsored by Rhode Island Hospital, which has 130 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02676544's enrollment target sits among peer trials
9 1955th of 2000 higher than 42 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia